| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/08/2001 | WO2001009183A2 Polymorphisms in the human mdr-1 gene and applications thereof |
| 02/08/2001 | WO2001009179A1 Moraxella cattarrhalis basb114 antigens and uses thereof |
| 02/08/2001 | WO2001009160A1 Nucleic acid ligands to cd40ligand |
| 02/08/2001 | WO2001009159A1 Nucleic acid ligands to hepatocyte growth factor/scatter factor (hgf/sf) or its receptor c-met and to integrins |
| 02/08/2001 | WO2001009155A1 Cloning of the streptomyces avermitilis genes for glycosylation of avermectin aglycones |
| 02/08/2001 | WO2001009146A1 Radiolabelled bisphosphonates and method |
| 02/08/2001 | WO2001009143A1 An improved amorphous form of cefpodoxime proxetil |
| 02/08/2001 | WO2001009142A1 Oxazinocarbazoles for the treatment of cns diseases |
| 02/08/2001 | WO2001009140A1 Thienopyranecarboxamide derivatives |
| 02/08/2001 | WO2001009139A1 Aromatic esters of camptothecins and methods to treat cancers |
| 02/08/2001 | WO2001009138A2 Chemokine receptor antagonists and methods of use therefor |
| 02/08/2001 | WO2001009136A1 1,2-dihydro-1-oxo-pyrazino[1,2-a]indole derivatives |
| 02/08/2001 | WO2001009134A1 Purine derivatives inhibitors of tyrosine protein kinase syk |
| 02/08/2001 | WO2001009133A1 NEW CYTOTOXIC PYRIDO[2,3,4-kl]ACRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
| 02/08/2001 | WO2001009132A1 C-6 RING-SUBSTITUTED PYRIDO[1,2-a]BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS |
| 02/08/2001 | WO2001009128A1 Thiourea and isothiourea derivatives for inhibiting ras-transformed cell growth |
| 02/08/2001 | WO2001009126A1 Serotonergic benzothiophenes |
| 02/08/2001 | WO2001009123A1 Benzofurylpiperazine serotonin agonists |
| 02/08/2001 | WO2001009122A2 Serotonergic benzofurans |
| 02/08/2001 | WO2001009121A2 2-pyrazolin-5-ones_as tyrosine kinase inhibitors |
| 02/08/2001 | WO2001009120A1 Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders |
| 02/08/2001 | WO2001009118A2 Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement |
| 02/08/2001 | WO2001009116A2 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)- 2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE |
| 02/08/2001 | WO2001009115A2 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1- YL)ETHOXY] PHENOXY)-2- (4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE |
| 02/08/2001 | WO2001009114A1 Hiv integrase inhibitors |
| 02/08/2001 | WO2001009113A2 Heterocyclic compounds inhibiting angiogenesis |
| 02/08/2001 | WO2001009111A1 Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists |
| 02/08/2001 | WO2001009110A1 Novel succinate derivative compounds useful as cysteine protease inhibitors |
| 02/08/2001 | WO2001009107A1 Oxazolidinones and their use as antiinfectives |
| 02/08/2001 | WO2001009106A1 Diamino-1,2,4-triazole-carboxylic and derivatives as gsk-3 inhibitors |
| 02/08/2001 | WO2001009103A2 Imidazole antiproliferative agents |
| 02/08/2001 | WO2001009101A1 Isoquinoline derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the active substance |
| 02/08/2001 | WO2001009097A1 Cyclic amine derivatives for the treatment of neurological diseases |
| 02/08/2001 | WO2001009096A2 Potassium channel openers |
| 02/08/2001 | WO2001009095A1 Mutilin derivatives and their use as antibacterials |
| 02/08/2001 | WO2001009093A1 Benzenamine derivatives as anti-coagulants |
| 02/08/2001 | WO2001009090A2 Hydantoin, thiohydantoin, pyrimidinedione and thioxopyrimidinone derivatives, preparation method and use as medicines |
| 02/08/2001 | WO2001009088A1 Urea derivatives as inhibitors of ccr-3 receptor |
| 02/08/2001 | WO2001009076A2 Retinoids for the treatment of emphysema |
| 02/08/2001 | WO2001009000A1 A device for spray dispensing a composition for topical application comprising vitamin e and essential fatty acids |
| 02/08/2001 | WO2001008714A1 Cartilage or bone matrix as a nucleic acid delivery vehicle |
| 02/08/2001 | WO2001008708A2 Enhanced delivery via serpin enzyme complex receptor ligands |
| 02/08/2001 | WO2001008707A2 Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes |
| 02/08/2001 | WO2001008705A1 Remedies for neurogenic pains |
| 02/08/2001 | WO2001008704A2 Dendrimer-photosensitizer complexes for medical applications |
| 02/08/2001 | WO2001008693A2 Combination therapy using pentafluorobenzenesulfonamide and platin compound |
| 02/08/2001 | WO2001008691A1 Methods for transdifferentiation of body tissues |
| 02/08/2001 | WO2001008689A1 Ophthalmic compositions containing antibiotics and nsaids |
| 02/08/2001 | WO2001008688A2 Beta-carboline drug products |
| 02/08/2001 | WO2001008687A1 Beta-carboline pharmaceutical compositions |
| 02/08/2001 | WO2001008686A1 Beta-carboline pharmaceutical compositions |
| 02/08/2001 | WO2001008685A1 Acyclic and cyclic amine derivatives |
| 02/08/2001 | WO2001008684A1 Nicotine in therapeutic angiogenesis and vasculogenesis |
| 02/08/2001 | WO2001008683A1 Nicotine receptor agonists in stem cell and progenitor cell recruitment |
| 02/08/2001 | WO2001008682A2 Use of flupirtine for alleviating pain caused by degenerative joint diseases in dogs and cats |
| 02/08/2001 | WO2001008681A1 Methods of administration of glycopyrrolate compositions |
| 02/08/2001 | WO2001008680A1 Preparations for reducing oxygen consumption during physical efforts |
| 02/08/2001 | WO2001008679A1 A method to increase the excretion of non-sterol endogenous hydrophobic substances by increasing excretion of fat via the faeces |
| 02/08/2001 | WO2001008678A1 Cis-2,6-disubstituted piperidines for the treatment of psychostimulant abuse and withdrawal, eating disorders, and central nervous system diseases and pathologies |
| 02/08/2001 | WO2001008677A1 Methods of inhibiting osteoclast activity |
| 02/08/2001 | WO2001008676A1 Assay for d-serine transport antagonist and use for treating psychosis |
| 02/08/2001 | WO2001008675A1 Use of agonists of gabab receptors and pharmaceutically acceptable derivates thereof, in the therapy of maintaining nicotine abstinence-dependent patients |
| 02/08/2001 | WO2001008674A1 Sulfonamide derivatives and remedies for allodynia |
| 02/08/2001 | WO2001008673A1 Calcilytic compounds |
| 02/08/2001 | WO2001008672A2 Glucamine compounds for treating hepatitis virus infections |
| 02/08/2001 | WO2001008671A2 Method and composition for prophylaxis and treatment of symptoms associated with cold and influenza-like illnesses |
| 02/08/2001 | WO2001008670A2 Methods and compositions for alleviating stuttering |
| 02/08/2001 | WO2001008669A2 Therapeutic agents for lymphoedema |
| 02/08/2001 | WO2001008668A2 Use of 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine in the treatment of gi disorders |
| 02/08/2001 | WO2001008667A2 2-aminotetralin derivatives for the therapy of glaucoma |
| 02/08/2001 | WO2001008665A1 Paracetamol controlled-release compositions |
| 02/08/2001 | WO2001008663A2 Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| 02/08/2001 | WO2001008662A1 Liquid pharmaceutical composition based on paracetamol |
| 02/08/2001 | WO2001008661A2 Opioid sustained-released formulation |
| 02/08/2001 | WO2001008652A1 Skin care composition |
| 02/08/2001 | WO2001008637A2 Treatment of premenstrual syndrome and menopause |
| 02/08/2001 | WO2001008635A2 Calcium channel transport polynucleotides, polypeptides, and antibodies |
| 02/08/2001 | WO2001008634A2 Polynucleotide encoding a human serine protease |
| 02/08/2001 | WO2001008633A2 An improved form of form i celiprolol hydrochloride |
| 02/08/2001 | WO2001008632A2 Colloidal composition for esthetic correction |
| 02/08/2001 | WO2001008505A2 Methods for suppressing appetite and enhancing exercise and recovery |
| 02/08/2001 | WO2001008496A1 Antiparasitic formulation |
| 02/08/2001 | WO2000076984A3 Novel compounds, their use and preparation |
| 02/08/2001 | WO2000075317A3 Compositions and methods for the treatment of tumor |
| 02/08/2001 | WO2000069855A3 Furanone derivatives as inhibitors of cathepsin s |
| 02/08/2001 | WO2000069520A3 Use of topical azathioprine to treat inflammatory bowel disorders |
| 02/08/2001 | WO2000067798A3 Enhanced delivery of nucleic acid-based drugs |
| 02/08/2001 | WO2000067769A8 Enhanced survival of cancer patients treated with erythropoietin and antitumor agents |
| 02/08/2001 | WO2000067708A3 Oral steroidal hormone compositions and methods of use |
| 02/08/2001 | WO2000066528A3 Quinones for treatment of diseases |
| 02/08/2001 | WO2000066141A3 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy |
| 02/08/2001 | WO2000064428A3 Polyether-based bile acid sequestrants |
| 02/08/2001 | WO2000063230A3 49 human secreted proteins |
| 02/08/2001 | WO2000061783A3 Process for preparing inhibitors of nucleoside metabolism |
| 02/08/2001 | WO2000061772A3 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
| 02/08/2001 | WO2000059851A8 Derivatives of venlafaxine and methods of preparing and using the same |
| 02/08/2001 | WO2000059525A3 USE OF ErbB RECEPTOR LIGANDS IN TREATING DIABETES |
| 02/08/2001 | WO2000058307A3 Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands |
| 02/08/2001 | WO2000058295A3 Compounds and methods for treatment of asthma, allergy and inflammatory disorders |
| 02/08/2001 | WO2000056737A3 Calanolides for inhibiting btk |